Skip to main content
Hector J. Santos-Villalobos, left, and Oscar A. Martinez

Two staff members at the Department of Energy’s Oak Ridge National Laboratory have received prestigious HENAAC and Luminary Awards from Great Minds in STEM, a nonprofit organization that focuses on promoting STEM careers in underserved 

3D-printed 316L steel has been irradiated along with traditionally wrought steel samples. Researchers are comparing how they perform at various temperatures and varying doses of radiation. Credit: Jaimee Janiga/ORNL

It’s a new type of nuclear reactor core. And the materials that will make it up are novel — products of Oak Ridge National Laboratory’s advanced materials and manufacturing technologies.

Solid radium sulfate sits in the bottom of a flask during the recovery process. Credit: Oak Ridge National Laboratory, U.S. Dept. of Energy

Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.

At the U.S. Department of Energy Manufacturing Demonstration Facility at ORNL, this part for a scaled-down prototype of a reactor was produced for industry partner Kairos Power.

Scientists at the Department of Energy Manufacturing Demonstration Facility at ORNL have their eyes on the prize: the Transformational Challenge Reactor, or TCR, a microreactor built using 3D printing and other new approaches that will be up and running by 2023.

Transformational Challenge Reactor Demonstration items

Researchers at the Department of Energy’s Oak Ridge National Laboratory are refining their design of a 3D-printed nuclear reactor core, scaling up the additive manufacturing process necessary to build it, and developing methods

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.